Monopar Therapeutics

Next generation targeted therapies for Wilson disease and cancer

[Monopar Therapeutics @MonoparTx]

Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients https://t.co/Al3WBOG6YT

[Monopar Therapeutics @MonoparTx]

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 https://t.co/DI6P4Mfq38

[Monopar Therapeutics @MonoparTx]

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 https://t.co/I6WRtdk9ME

[Monopar Therapeutics @MonoparTx]

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate https://t.co/lWwfgbQ1Mx

[Monopar Therapeutics @MonoparTx]

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Radiopharma Program at EANM 2024 https://t.co/XWdwOy8iJU

[Monopar Therapeutics @MonoparTx]

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients https://t.co/wrnGxGxwre

[Monopar Therapeutics @MonoparTx]

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program https://t.co/M2FhjQjUOK

[Monopar Therapeutics @MonoparTx]

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
https://t.co/UfJ2Jeda9Z

[Monopar Therapeutics @MonoparTx]

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
https://t.co/RDQclFcYl7

[Monopar Therapeutics @MonoparTx]

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
https://t.co/8F2n8AT9SE

[Monopar Therapeutics @MonoparTx]

Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration https://t.co/zQge8GLIey

[Monopar Therapeutics @MonoparTx]

Abstracts for the ASH 2022 Conference were released today, please find Monopar's here! https://t.co/NTFvRYX10V

[Monopar Therapeutics @MonoparTx]

Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202 https://t.co/Q8RC0hJiwG

[Monopar Therapeutics @MonoparTx]

Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting

https://t.co/JkwXKsDQMq

[Monopar Therapeutics @MonoparTx]

Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting

https://t.co/fowQfyDcZZ

[Monopar Therapeutics @MonoparTx]

Scholars join forces on anti-cancer drug: https://t.co/O2nI9Umgxe

[Monopar Therapeutics @MonoparTx]

Monopar Announces Clinical and Preclinical Program Updates https://t.co/cK7x9EqchL

[Monopar Therapeutics @MonoparTx]

Monopar to Present at the H.C. Wainwright BioConnect Conference https://t.co/xhZnhhXKLU

[Monopar Therapeutics @MonoparTx]

Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial https://t.co/xZLc5nXZvr

[Monopar Therapeutics @MonoparTx]

Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments https://t.co/wUHXvbY63X